[ad_1]
“Until now, there is no rational basis for ordering this Russian product, which has cheaper, more effective and more reliable vaccines in its segment,” he said Sunday.
A. Žumadilovas emphasized that competition in the segment of vector vaccines, such as the first vaccine developed by Russia “Sputnik V”, is high.
“There are 18 manufacturers in the world at the same time [vakcinos] Developing. These include such respected players in the international pharmaceutical market as AstraZeneca, Johnson & Johnson, and others. At the same time, AstraZeneca already has permission to distribute its vaccine in several countries, including the UK, ”he said.
Sputnik V clinical trials have been completed or are ongoing in Russia, Belarus, the United Arab Emirates, Venezuela, India, and a few other countries.
Russia boasts that Sputnik V is “the world’s first registered vaccine against COVID-19.” Supervisory authorities granted permission to distribute it as early as August. The move was criticized by international experts, who noted that the vaccine had only been tested on a few dozen people at that time.
Meanwhile, Russian President Vladimir Putin is not vaccinating the vaccine and said last month that it has not yet been given to people his age.
[ad_2]
